We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing our proprietary bile acid chemistry. Our product candidates have the potential to treat orphan and more prevalent diseases for which there currently are limited therapeutic solutions.
Our Lead Product Candidate
Our lead product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. OCA is a first-in-class product candidate that selectively binds to and induces activity in the farnesoid X receptor, or FXR, which we believe has broad liver-protective properties. We are developing OCA initially for primary biliary cirrhosis, or PBC, as a second-line treatment for patients who have an inadequate response to or who are unable to tolerate standard-of-care therapy and therefore need additional treatment. PBC is a chronic autoimmune liver disease that, if inadequately treated, may eventually lead to cirrhosis, liver failure and death.
We own worldwide rights to OCA outside of Japan and China, where we have exclusively licensed the compound to Sumitomo Dainippon Pharma, or SDP, and granted it an option to exclusively license OCA in certain other Asian countries.